Introduction
Squamous cell carcinoma of the head and neck represents the sixth most common malignant cancer worldwide. Most of them are squamous cell carcinomas of the oral cavity [oral squamous cell carcinoma (OSCC)] (1). In spite of recent advances in therapeutic treatment, OSCC has seen little improvement concerning mortality rates over decades (2, 3) . Overall 5 year survival rate is still $50%. This underlines the importance to explore novel molecular markers and targets, which could help to optimize diagnosis and treatment of OSCC.
Recently, there is growing evidence that a new gene, the human homolog of Drosophila headcase (HECA), plays an important role in human carcinogenesis (4, 5) . The 59 kDa HECA protein is highly conserved and belongs to a new class of cell differentiation regulators of the HECA family [KOG3816, COG-Database: Clusters of orthologous groups for eukaryotic complete genomes (6) ]. In Drosophila, headcase (hdc) regulates the re-entry of imaginal cells into the mitotic cycle during adult morphogenesis (7) and also inhibits terminal branching of neighboring cells during tracheal development (8) . Furthermore, Drosophila hdc is a specific suppressor of stat92E, an ortholog of human stat5A, indicating a role for HECA in the JAK/STAT pathway (28) . The dysregulation of Stat5A is associated with a wide range of human malignancies, including cancer (9) . Interestingly, the human HECA gene locus is mapped to chromosome 6q23-24, a known loss-of-heterozygosity region of genes related to tumor diseases, including head and neck cancers (10, 11) . In normal tissues, the HECA gene is ubiquitously expressed at a basal level, with the highest expression in spleen, prostate and peripheral blood leukocytes (4) . However, in malignant neoplasms an altered HECA expression was found. In pancreatic and renal cancer cells only a low expression of HECA could be detected. Together with its chromosomal location, being a region of common deletion in human pancreatic cancer, HE-CA was suggested to be a tumor suppressor (5) . Moreover, studies on colorectal cancer have revealed a significant correlation of HECA expression and disease status. Due to this, human HECA is supposed to be an effective marker for early-stage colorectal cancer (4) .
Although the literature suggests a significant role for HECA in several tumor entities, the published data are only based on expression analysis at transcriptional level. In the present study, we investigated the HECA mRNA and protein expression in human oral keratinocytes (HOKs) and OSCC. Our study shows for the first time the functional effects of human HECA in OSCC cells and conveys how increased expression levels might influence OSCC malignancy. Furthermore, we provide evidence that HECA affects the proliferation of OSCC cells and slows down their cell division. Human HECA may therefore act as a tumor suppressor in head and neck cancer.
Materials and methods

Cells and cell culture
The human OSCC cell lines (PCI series) used in this study were kindly provided by Prof. T.L.Whiteside (University of Pittsburgh Cancer Institute, Pittsburgh, PA). The OSCC cell lines were established from primary tumors in the laboratory at the University of Pittsburgh as described previously (12) . The tumor cell lines were maintained as published elsewhere (13) .
The primary cell line normal human keratinocyte (NHEK) was obtained from PromoCell (Heidelberg, Germany) and derived from human adult keratinocytes. The primary human cell line HOK was obtained from ScienCell (SanDiego, CA) and was established using human fetal keratinocytes. Cell culturing of both, NHEKs and HOKs, was carried out according to the manufacturer's instructions.
Tissue samples
Archival formalin-fixed and paraffin-embedded OSCC tissues and control samples were obtained from the Department of Oral and Maxillofacial Surgery at the Johannes Gutenberg University (Mainz, Germany) and were used for immunohistochemical studies.
Plasmids
The HECA full-length clone, IRAKp961L14168Q-end sequence verified clone, was purchased from imaGenes (formerly RZPD, Berlin, Germany) and the entire coding region of HECA complementary DNA (cDNA) (without both the 5#-and 3#-untranslated regions) was subcloned from the pBluescriptR vector into the pcDNA3.1D/V5-His-TOPO vector (Invitrogen, Karlsruhe, Germany), containing a cytomegalomavirus promoter and the selectable marker for neomycin resistance. The plasmid-HECA construct was confirmed by sequencing.
Stable HECA-transfections Stable transfections of OSCC cells were performed using FuGENE HD Transfection Reagent (Roche Applied Science, Mannheim, Germany), according to manufacturer's protocol. To establish OSCC lines constitutively overexpressing the full-length HECA, the OSCC cell line PCI 13 was transfected with the plasmid-HECA construct and afterward selected for resistance to 1.6 mg/ml of geneticin (Invitrogen). As controls, PCI 13 received an insert-free pcDNA3.1D/ V5-His-TOPO vector (denominated as mock control) or remained untransfected. For testing of HECA overexpression, RNA from the cell clones was isolated and cDNA synthesized for quantitative real-time polymerase chain reaction (qPCR) applying LightCycler technology (Roche Applied Science).
Immunochemistry
For immunochemical staining, the mouse polyclonal antibody anti-HECA (dilution: 1:50 for tissue, 1:100 for cell culture; Abnova, Heidelberg, Germany) was used. Immunohistochemistry of formalin-fixed paraffin-embedded human oral tissue was performed as described by Bauer et al. (14) . Immunocytochemistry of cultured cells was done following the protocol published in Müller-Richter et al. (15) .
Western blot analysis
Protein extraction and western blotting cell culture supernatants were performed according to the procedure described previously (14) with minor modifications. For detection of the HECA protein, we used the mouse polyclonal antibody anti-HECA (Abnova GmbH, Heidelberg, Germany) with the dilution 1:1000. For detection of the housekeeping protein b-actin, we applied the rabbit polyclonal antibody anti-b-Actin (ab8227, Abcam, Cambridge, MA) with the dilution 1:10 000. Figure 2A shows a representative blot of three individual experiments.
Quantitative real-time polymerase chain reaction Isolation of total cellular RNA from cultured cells and reverse transcription were performed following the protocol published in Bauer et al. (14) with some modifications. First-strand cDNA was synthesized from 2 lg of total RNA using the Transcriptor First-Strand cDNA Synthesis Kit (Roche Applied Science) according to the manufacturer's instructions.
The gene expression of HECA was determined by qPCR applying the LightCycler technology (Roche Applied Science), normalized to the housekeeping gene b-actin. We amplified cDNA using the LightCycler TaqMan Master kit (Roche Applied Science) in combination with the Universal ProbeLibrary System according to manufacturer's protocols. Real-time PCR primers for HECA (HECA forward: 5#-GCACTATgTACACCTACgACATCC-3#; HECA reverse: 5#-TCCCACAgTgCTTACAgTTCA-3#) and b-actin (b-actin forward: 5#-ccaaccgcgagaagatga-3#; b-actin reverse: 5#-tccatcacgatgccagtg-3#) were obtained from TibMolBiol (Berlin, Germany). The corresponding UPL-Probes (for HECA: probe no. 34; for b-actin: probe no. 64) were purchased from Roche Applied Science.
Cell phase synchronization
The synchronization of tumor cells was performed as described previously (13) with minor modifications. After synchronized cells were allowed to grow for 6 h, they were harvested for RNA isolation and subsequent qPCR analysis. The protein analysis after synchronisation is described in supplementary Methods S2 (available at Carcinogenesis Online).
Cell proliferation assays
The number of viable cells and the proliferation activity were measured simultaneously using the WST-1 assay and the BrdU enzyme-linked immunosorbent assay (chemiluminescent) assay (both from Roche Applied Science) as described by the manufacturer. Briefly, 500 cells were seeded in a 96-well microplate in triplicates and cultured for 2 h. After adding 10 ll per well BrdU labeling solution, the cells were incubated for 18 h. Meanwhile, 10 ll per well WST-1 reagent was added and the cells were reincubated for another 3 h. The color intensity was measured at 450 nm wavelength with a Tecan GENios microplate reader (Tecan, Crailsheim, Germany). Then the microplate was emptied and further processed according to manufacturer's BrdU enzymelinked immunosorbent assay protocol. The light emission was measured using the same microplate reader.
Cell cycle analysis Nuclear DNA content was determined performing propidium iodide staining and subsequent flow cytometry analysis. The cells were cultivated up to 50-60% confluence and dissociated with Accutase (PAA Laboratories). After adding ice-cold medium, the cells were centrifuged and resuspended in ice-cold buffer (phosphate-buffered saline without Ca þþ Mg þþ , 2% bovine serum albumin) for counting. A total of 5 Â 10 5 cells were fixed in ice-cold 70% ethanol for 1 h at 4°C, washed twice with buffer and resuspended in buffer. Fixed cells were treated with RNase (0.1 mg/ml; Roche Applied Science) for 30 min at 37°C, stained with propidium iodide (50 lg/ml; Sigma-Aldrich, Steinheim, Germany) and kept in the dark on ice for 10 min before analysis. Cell cycle analysis was carried out using a FACSCanto flow cytometer (BD Biosciences, Heidelberg, Germany) and data were analyzed with the ModFit LT software (Verity Software House, Topsham, ME).
Apoptosis assay
For detection of apoptosis, cells were stained simultaneously with fluorescein isothiocyanate-conjugated annexin V and propidium iodide using the AnnexinV:fluorescein isothiocyanate assay kit (AB Serotec, Düsseldorf, Germany) according to manufacturer's instructions. Flow cytometry was performed applying a FACSCanto flow cytometer and data analysis was carried out using FACSDiva Software (both from BD Biosciences).
Drosophila stocks and histology Drosophila-related assays are described in supplementary Method S1 (available at Carcinogenesis Online).
Statistical analysis
Columns in all figures show the mean value of at least three independent measurements. All statistical analyses were done using the Student's t-test, and P values of ,0.05 were considered as significant.
Results
Expression of HECA protein in normal oral mucosa and OSCC Immunohistology of tissue slices and cell lines. To date, the expression and function of HECA protein in the human oral tissue and its malignant neoplasms have not been characterized, although HECA mRNA has been detected in a variety of human normal and tumor tissues (4, 5) and its potential role in malignant progression is becoming more apparent.
In this study, we analyzed the expression of HECA protein in vivo in human oral epithelium by immunohistochemistry of sections taken from normal mucosa and human OSCC tissue. In healthy oral mucosa, an expression of HECA was observed in both the basal keratinocytes and the suprabasal cell layers. HECA expression was not confined to the cytoplasm, with clear nuclear staining (Fig. 1A) . In contrast, OSCC exhibits a weaker cytoplasmatic and nuclear HECA signal, without a marked expression in the basal keratinocytes (Fig. 1B) . In vitro, we evaluated HECA expression by immuncytochemistry in two primary cell lines, HOKs and NHEKs, as well as in several OSCC cell lines (PCI1, PCI 9, PCI 13 and PCI 52). HECA stainings in HOKs ( Figure 1C ) and NHEKs were strong in the cytoplasm, accompanied by slight nuclear signals, whereas all OSCC cell lines ( Figure 1D ) revealed mainly to the cytoplasm-restricted staining.
Immunoblot analysis of cell lysates of HOKs and OSCC lines.
To analyze HECA expression in OSCC cell lines, western blot analysis of four OSCC cell lines (PCI 4, PCI 9, PCI 13 and PCI 52) was performed. Figure 2A reveals the full-length HECA protein with its molecular mass of 59 kDa in both HOKs and two OSCC cell lines (PCI 9 and PCI 13). However, full-length HECA expression is virtually absent in the other two OSCC cell lines (PCI 4 and PCI 52). Interestingly, in all OSCC cell lines, we observed additional truncated HECA versions with a molecular mass either higher or lower than the full-length 59 kDa protein and with apparently different expression levels. In HOKs, the additional HECA versions could not be detected.
qPCR with mRNA from transfected cell lines. To examine HECA expression in OSCC lines on mRNA level, we performed qPCR studies ( Figure 2B ). Compared with HOKs, a higher or the same HECA mRNA expression was measured in two OSCC lines (PCI 13 and PCI 9), whereas the two OSCC cell lines PCI 4 and PCI 52 had reduced HECA expression levels. With regards to full-length HECA, the mRNA expression corresponds to protein signals of the immunoblot analysis. Both the mRNA and protein signals of the OSCC cell lines PCI 13 and PCI 9 were more increased than those of PCI 4 and PCI 52. In our previous studies (14), we have determined the status of cellular differentiation in our OSCC cell lines via analysis of the expression level of certain cytokeratin makers. We found out that HOKs and PCI 13 consist of cells still capable of differentiating, whereas in PCI 4 and PCI 52 only markers for undifferentiated or proliferating cells could be detected. Notably, the last-mentioned cell lines were those with the lowest HECA mRNA and protein signals.
Disordered cell proliferation in Drosophila HECA mutants
The biology of the fruit fly Drosophila melanogaster provides a valid model for cancer research (18) . The dysregulation of most genes and signaling pathways in the fly results in well-known hallmarks of Headcase affects cell cycle of OSCC cancer-loss of tissue architecture, overproliferation, differentiation and increased invasion (19) .
To demonstrate the requirement of a functional Drosophila headcase for both, cell proliferation and correct architecture of the larval brain, we have analyzed the development of the D.melanogaster optic lobe. Initially, we labeled mitotic cells of third instar visual system in a BrdU incorporation assay and detected them with an anti-BrdU antibody. BrdU stainings revealed a disruption of the regular mitotic layers of neuroblasts in the optic lobe of homozygous headcase mutants (supplementary Figure S1B is available at Carcinogenesis Online), compared with wild-type flies (supplementary Figure S1A is available at Carcinogenesis Online).
In further immunohistological studies of these homozygous hdc-deficient optic lobes with a glia-specific cell marker, we have observed defect patterns of the glial cells (supplementary Figure S1C and D is available at Carcinogenesis Online), which play a key role in the stratification of the flies visual system (21).
Increased HECA mRNA expression in S-phase of OSCC cells The Drosophila literature confirms our results shown above giving evidence for a role of HECA in cell cycle regulation. The Drosophila headcase protein interacts with Cyclin K (22) and with Bub1-like Protein (23), which is a mitotic cycle checkpoint protein.
Both literature data and our findings have brought us to study the functional influence of human HECA on proliferation of OSCC cells in detail.
First, we analyzed the HECA mRNA expression in the OSCC cell line PCI 13 synchronized in different cell cycle phases, using serum starvation for G 1 /G 0 arrest and Aphidicolin treatment for S-phase arrest, respectively. The untreated control does not include synchronized OSCC cells and therefore consists of a mixture of all cell cycle phases. Figure 2C Cloning of HECA and analysis of HECA-transfected OSCC cell line PCI 13 To prove our assumption, we established OSCC cell lines stably expressing full-length HECA protein. The plasmids thereto were constructed by cloning the entire coding region of HECA cDNA into the pcDNA3.1-TOPO expression vector and transfected in the OSCC line PCI 13.
In the following functional studies, we compared two individual clones (clone 1 and clone 2) of the HECA-overexpressing OSCC cell line PCI 13 with mock controls and untransfected parental control cells ( Figure 2D ).
Decreased doubling time and proliferation activity of HECAoverexpressing OSCC cells If HECA influences the cell cycle, we would have expected an impact on both the cell growth and the cell division. To test this hypothesis, we performed simultaneous measurements of viability and proliferation of the HECA-transfected OSCC cell line. The number of viable cells was determined via WST-1 assay and the doubling time for each cell line was calculated.
In HECA-overexpressing cell clones, we observed a significantly lower number of viable cells at the end of the observation period and therefore a significantly prolonged doubling time up to 45% ( Figure  3A and B). The BrdU enzyme-linked immunosorbent assay assays confirmed that this attenuation is due to a significantly lower number of mitotically active cells up to 30% ( Figure 3C ). We concluded that HECA impairs the proliferation of OSCC cells in vitro.
HECA overexpression increases the number of cells in G 2 /M-phase
Based on these findings, we performed flow cytometry analysis of propidium iodide-stained HECA-overexpressing cell clones and controls to examine the cell cycle ( Figure 4A ). It could be demonstrated A. Dowejko et al. that the fraction of HECA-overexpressing cell clones that retained in the G 2 /M-phase was significantly higher than the fraction found within mock-transfected and non-transfected control cells ( Figure  4B ). The percentage of cells detected in G 0 /G 1 -phase was significantly lower only between HECA clones and Mock cells, but not between HECA clones and wt cells. The fraction of cells found out in S-phase did not differ significantly between HECA clones and controls (data not shown).
No change in apoptosis of HECA-overexpressing OSCC cells
To exclude that the impairment of proliferation in HECAoverexpressing OSCC cell clones were due to an increase of apoptosis or necrosis, annexin V/propidium iodide-flow cytometry analysis was carried out ( Figure 5A ). Only marginal early apoptosis (,2%) and low late apoptosis/necrosis (,8%) could be detected, with no significant difference between HECA clones and controls ( Figure 5B ). The data indicate that HECA overexpression does not affect apoptosis or necrosis, which implies that HECA expression have cytostatic but not cytotoxic effects on OSCC cells.
Discussion
The present study provides new insights in malignant progression of head and neck cancer. Here, we demonstrate that upregulated HECA, a human homolog of Drosophila headcase, significantly suppresses the cell division of OSCC cells in vitro.
Initially, we could detect a marked HECA protein expression in vivo in normal oral epithelium, but a weaker HECA staining in OSCC tissue, which is missing in the basal cells. In vitro analysis of HECA expression in OSCC cell lines via western blot and qPCR reveals that the expression of full-length HECA depends on the state of OSCC cell differentiation. OSCC lines capable of differentiation (PCI 9 and PCI 13) showed higher HECA expression levels than undifferentiated and proliferating OSCC cells (PCI 4 and PCI 52), respectively. These data are in line with our Drosophila studies where HECA-deficient larval brains showed an aberrant pattern of cell proliferation and abnormal tissue architecture. In further functional analysis of human OSCC cells, we discovered a significant impact of human HECA on both cell cycle and proliferation. First, OSCC cells synchronized in S-phase expressed more HECA mRNA and protein than cells in G 0 /G 1 -phase. Second, overexpression of HECA in OSCC cells resulted in a prolonged doubling time. BrdU studies verified that this was due to a decline of mitotically active cancer cells. Third, flow cytometry analysis revealed that overexpression of HECA forced cells to retain in G 2 /M-phase of the cell cycle. Finally, we found in flow cytometry assays that HECA overexpression does not affect apoptosis, implying that HECA expression has cytostatic but no cytotoxic effects on OSCC cells.
As mentioned above Drosophila is a valid model for cancer research and therefore, we can learn a lot about the human HECA from Drosophila-related studies (18,19) . The present study and the data published associate both the human HECA and the Drosophila HECA Headcase affects cell cycle of OSCC with cell proliferation and differentiation. There is a clear line of evidence that human HECA might be a regulator of cell proliferation and could act as a tumor suppressor in head and neck cancer.
It is well known that the human oral epithelium underlies a high turnover rate of cells. Basal layer cells undergoing mitosis, while differentiating, migrate to the surface layer. Interestingly, we observed a HECA protein expression in the proliferating basal cells as well as in the differentiating cells of the superficial layers. In OSCC tissue, the overall HECA staining was weaker and more diffuse and is missing in the basal cell layer. Due to these findings, we assumed that the loss of HECA expression in oral cells lead to a defective proliferating control of basal cells and/or aberrant differentiation of keratinocytes, which may result in neoplastic formation of the oral epithelium.
This hypothesis was corroborated through in vitro studies, where oral cell lines capable to differentiate (HOK, PCI 13 and PCI 9) exhibited a much stronger HECA expression level as dedifferentiated cell lines (PCI 4 and PCI 52). Immunoblot analyses revealed the HECA full-length protein exclusively in the cells capable of differentiating. It is noteworthy that only OSCC cells showed additional HECA versions, which were absent in normal HOKs. We considered that expression of full-length HECA is required for differentiation of oral cells. Moreover, the detection of alternative HECA versions could be linked to malignancy state of oral cancer cells and might be a helpful diagnostic marker in OSCC, like alternative forms of other proteins as P-Cadherin (14), Tenascin-C or Laminin-5 (24).
Human HECA itself is already described as a prognostic parameter in colorectal cancer, which can discriminate between late-and earlystage disease (4) . In further investigations, the significance of the HECA variants for tumor progression in head and neck squamous cell carcinoma has to be determined. Interestingly, Drosophila headcase mRNA encodes two overlapping protein products, a functional fulllength hdc and a truncated form with retarded functionality (8, 25) . This could be an examination model to uncover the significance of the human HECA variants in normal and malignant oral tissues.
The human HECA protein has a 59% similarity (42% identity) to Drosophila headcase [NCBI: BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.18 [Mar-02-2008] (5,26)], indicating that HECA studies in Drosophila provide important data to uncover HECA function in human tissues. In immunohistological analyses of hdc-deficient Drosophila larval brains, we confirmed our suggestion that a functional HECA (including human HECA) is needed for both cell proliferation and differentiation. Our investigations of the developing optic lobe demonstrated that expression of hdc is obligate for wild-type structure of mitotic layers of lamina and glia precursor cells. These data are in line with published observations that Drosophila hdc is expressed at sites of intense cell proliferation (7, 27) or cell shape changes (8) . Furthermore, Weaver et al. (7) show the requirement of Drosophila headcase for the differentiation of the optic lobe; they observed that hdc expression prefigures imaginal cell re-entry in the mitotic cycle and persists until the final cell division, suggesting a role for HECA in the timing of proliferation. Moreover, Bach et al. (28) performed a deficiency screen and reported that Drosophila hdc specifically suppresses the enlarged eye phenotype which is caused by an activated JAK/STAT pathway -the enlarge eye phenotype is a result of an increased cell number, but not cellular volume, and arises from additional mitoses in larval eye discs. Thus, hdc attenuates mitosis and proliferation. The inhibitory character of the HECA protein is also reflected by studies of Steneberg et al. (8) . They found out that hdc is involved in tracheal development of Drosophila, where it acts non-autonomously in an Headcase affects cell cycle of OSCC inhibitory signaling mechanism to determine the number of cells that will form unicellular sprouts in the trachea.
As initially described, Drosophila literature also report on interactions between hdc and Cyclin K (22) as well as Bub-like-1 (23), which link HECA to cell cycle regulation. Notably, human Cyclin K is a direct transcriptional target of the p53 tumor suppressor (29) .
Based on these findings and our Drosophila studies, we performed subsequent functional studies to validate our hypothesis that human HECA has a significant impact on both cell cycle regulation and cell proliferation in the oral epithelium and OSCC. At first, we detected in aphidicolin experiments with the OSCC line PCI 13 a higher HECA expression in mitotically active S-Phase cells, indicating a role for HECA in mitosis. Given this, we analyzed how an ectopic HECA protein influence the proliferation and cell cycle progression of oral cancer cells. Therefore, we generated cell clones derived from the OSCC line PCI13, stably overexpress the full length HECA. We provide evidence that ectopic HECA significantly reduce the number of viable OSCC cells, with an increased doubling time up to 45% (17 h). In BrdU studies, we have shown that this prolonged doubling time was accompanied with a significant decrease in the number of mitotically active cancer cells up to 30%.
To explain this effect on molecular level, it may be speculated about both the upstream and the downstream signaling of HECA. First, the pathway upstream of HECA is discussed. It is well known that Drosophila hdc expression is positively regulated by the transcription factor escargot (esg) (8) . The human homolog to escargot is called SLUG (synonymous for SNAIL2), which represent a key player in epithelial-mesenchymal transition. Epithelial-mesenchymal transition appears to be critical for tumor progression associated with invasion and metastasis (30) . There is a substantial body of data to implicate SLUG in regulation of human HECA. Likewise HECA, the SLUG protein is expressed in basal keratinocytes of human epithelium and activation of slug results in reduced cell proliferation (31) . Moreover, SLUG overexpression forced epithelial MDCK cells (Madin-Darby canine kidney epithelial cell line) to arrest in G 1 and G 2 /M cell phase (32) , which is in line with our proliferation analysis of HECA-overexpressing OSCC cells. Furthermore, the HECA gene reveals many (.30) E-box motifs (CANNTG; two E-box motifs within 600 bp upstream of the transcription start site; A.Dowejko, unpublished data), at which SLUG binds to DNA and exerts its action (31) . Finally, HECA as well as SLUG were found to act in same disease context and were identified as biomarkers for colorectal cancer (4, 33) .
Concerning the signaling pathway downstream of HECA, it could be suggested of the following mechanisms. Recently, Alper et al. (34) found out, that after RNAi-mediated silencing of HECA in mouse, the expression of the proinflammatory interleukin (IL)-6 was decreased. IL-6-types cytokines play an important role in the regulation of complex cellular processes such as gene activation, proliferation and differentiation. Interestingly, the second phase of tumorigenesis, tumor promotion, is characterized by the clonal expansion of initiated cells, owing to increased cell proliferation and/or reduced cell death. Karin et al. (35) reported on the clear link between carcinogenesis and inflammation. They noticed that inflammatory cells and the innate immune system are important mediators of tumor promotion and progression, and several cytokines-such as IL-1, IL-6 and tumornecrosis factor-can promote tumor growth. Given this, we assumed that HECA might regulate IL-6-mediated tumor cell proliferation.
Another or redundant HECA downstream signaling that could be discussed involves the JAK/STAT pathway. head and neck squamous cell carcinoma is considered to develop in a multistep process from normal oral epithelium to an invasive carcinoma through genetic instabilities concerning oncogenes or tumor suppressor genes, including epidermal growth factor receptor and epidermal growth factor receptor-mediated signaling pathways such as JAK/STAT (2). Moreover, Constantinescu et al. (36) state that several cancers exhibit constitutive STAT activation, including head and neck squamous cell carcinoma (37) . As mentioned in the introductory, Drosophila headcase is a specific suppressor of an activated JAK/STAT pathway (28) . According to this view, it could be speculated that human HECA regulate JAK/STAT signaling negatively and acts compensatory on hyperactivation of STATs. Therefore, reduced expression level of HECA in OSCC possibly could not compensate constitutively activated STAT. Clearly, further work has to be done to elucidate the relevant biochemical interactions and functional implications between HECA and its putative binding partners in carcinogenesis.
Together, our data indicate that human HECA has a suppressive impact on the cell division of oral cancer cells, suggesting HECA as a new tumor suppressor.
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